美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Pasithea Therapeutics Corp Warrant

0.0100

0.0000

成交量：- -

成交額：- -

市值：7.44萬

市盈率：0.00

高：0.0100

開：0.0100

低：0.0100

收：0.0100

52周最高：0.1198

52周最低：0.0100

股本：744.36萬

流通股本：744.36萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-5.2115

淨資產收益率：-8.41%

總資產收益率：-10.52%

市淨率：0.00

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Pasithea Therapeutics獲得ALS協會100萬美元資金，研究Pas-004在治療ALS中的療效、安全性和耐受性

Pasithea Therapeutics宣佈在晚期癌症患者中完成Pas-004的第7組階段I臨床試驗，取得積極的安全性、藥代動力學（Pk）和藥效動力學（Pd）數據

Pasithea Therapeutics公布在成人NF1患者中進行的1/1B期試驗中Pas-004片劑的積極藥代動力學（Pk）數據

Pasithea Therapeutics Corp.宣佈在韓國啓動Pas-004治療成人NF1患者的1/1B期臨床試驗點

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/KTTAW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"KTTAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTAW\",,,,,undefined,":{"symbol":"KTTAW","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp Warrant","latestPrice":0.01,"timestamp":1774036800000,"preClose":0.01,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":7443563,"shares":7443563,"eps":-5.2115,"marketStatus":"休市中","change":0,"latestTime":"03-20 16:00:00 EDT","open":0.01,"high":0.01,"low":0.01,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.2115,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"listingDate":1631678400000,"exchange":"NASDAQ","adjPreClose":0.01,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTAW\",,,,,undefined,":{"symbol":"KTTAW","floatShares":7443563,"roa":"-10.52%","roe":"-8.41%","lyrEps":0,"shares":7443563,"dividePrice":0,"high":0.01,"amplitude":0,"preClose":0.01,"low":0.01,"week52Low":0.01,"pbRate":"0.00","psRate":"1.76","week52High":0.1198,"institutionHeld":0,"latestPrice":0.01,"eps":-5.2115,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.2115,"open":0.01,"prevYearClose":0.0141,"prevWeekClose":0.0109,"prevMonthClose":0.0102,"prevQuarterClose":0.0141,"fiveDayClose":0.0109,"twentyDayClose":0.012,"sixtyDayClose":0.0162},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTAW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTAW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTAW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1167809601","title":"Pasithea Therapeutics獲得ALS協會100萬美元資金，研究Pas-004在治療ALS中的療效、安全性和耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1167809601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167809601?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 20:02","pubTimestamp":1764072154,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics获得ALS协会100万美元资金，用于研究Pas-004在治疗肌萎缩侧索硬化症（ALS）中的疗效、安全性和耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0},{"id":"1111694989","title":"Pasithea Therapeutics宣佈在晚期癌症患者中完成Pas-004的第7組階段I臨床試驗，取得積極的安全性、藥代動力學（Pk）和藥效動力學（Pd）數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1111694989","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111694989?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 20:02","pubTimestamp":1763985763,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验，取得积极的安全性、药代动力学（Pk）和药效动力学（Pd）数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0},{"id":"1179978808","title":"Pasithea Therapeutics公布在成人NF1患者中進行的1/1B期試驗中Pas-004片劑的積極藥代動力學（Pk）數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1179978808","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179978808?lang=zh_tw&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746513,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics公布在成人NF1患者中进行的1/1B期试验中Pas-004片剂的积极药代动力学（Pk）数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTAW","BK4139","KTTA"],"gpt_icon":0},{"id":"1126813537","title":"Pasithea Therapeutics Corp.宣佈在韓國啓動Pas-004治療成人NF1患者的1/1B期臨床試驗點","url":"https://stock-news.laohu8.com/highlight/detail?id=1126813537","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126813537?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 19:03","pubTimestamp":1758020605,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp.宣布在韩国启动临床试验点，用于开展Pas-004药物治疗成人NF1患者的1/1B期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}